Japan Grants Global First Nod For Brodalumab, For Psoriasis
This article was originally published in PharmAsia News
Executive Summary
Japan has granted the first approval worldwide for brodalumab as a biologic therapy for psoriasis, one of two new antibodies for the disorder in a new batch of approvals that also includes Praluent and Kyprolis.
You may also be interested in...
Celgene’s Otezla Gets Preliminary Nod From NICE At Second Attempt
Celgene’s near-blockbuster oral psoriasis drug Otezla is cleared by NICE in a second draft guidance for use in severe psoriasis, after the company comes up with an acceptable patient access scheme.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.